Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

Autor:	Ursula Sessa, Maria Celentano, Stefano Rocco, Rossella Fabbricini, Olimpia Finizio, Vincenzo Mettivier
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	Chronic myeloid leukemia Optimal response Nilotinib Medicine (General) R5-920
Zdroj:	Clinical Management Issues, Vol 6, Iss 2S, Pp 11-14 (2015)
Druh dokumentu:	article
ISSN:	1973-4832 2283-3137
DOI:	10.7175/cmi.v6i2S.1138
Popis:	Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological response after one month of treatment.After about 3 months the patient presented a complete cytogenetic response and after six months major molecular response (MR3). At nine months of treatment the patient presented a complete molecular response (MR4).
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/52a2341672a54f938c2de15a524c96e6 Zobrazit plný text záznamu View record in DOAJ